"Once Bitten, Twice Shy": Participant perspectives in the aftermath of an early HIV vaccine trial termination

Vaccine

Volumn 29, Issue 3, 2011, Pages 451-458

  Newman, P A ^a   Yim, S ^a   Daley, A ^b   Walisser, R ^a   Halpenny, R ^c   Cunningham, W ^d   Loutfy, M ^c,e  

^a UNIVERSITY OF TORONTO   (Canada)

^b YORK UNIVERSITY   (Canada)

^c Canadian Immunodeficiency Research Collaborative   (Canada)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF TORONTO   (Canada)

Author keywords

Early termination of clinical trials; HIV vaccines; Information dissemination; Research subject recruitment; Step Study

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; PLACEBO;

ADULT; ARTICLE; BISEXUAL MALE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEALTH SURVEY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; INFORMATION DISSEMINATION; INTERPERSONAL COMMUNICATION; MALE; MEDICAL ETHICS; MULTICENTER STUDY; PATIENT COUNSELING; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SELF CONCEPT; SEMI STRUCTURED INTERVIEW; THEMATIC ANALYSIS; TREATMENT OUTCOME; UNCERTAINTY; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; AIDS VACCINES; EARLY TERMINATION OF CLINICAL TRIALS; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; PATIENT PARTICIPATION; QUESTIONNAIRES; VACCINATION; YOUNG ADULT;

EID: 78650524325     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.10.076     Document Type: Article

References (35)

1. Rerks-Ngarm S., Pitisuttithum P., Nitayaphan S., Kaewkungwal J., Chiu J., Paris R., et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 Infection in Thailand. N Engl J Med 2009, 23(361):2209-2220.
2. Michael N. RV 144 Update: Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thai Adults. 17th Conference on retroviruses and opportunistic infections (CROI): Abstract 74. Presented February 18, 2010 http://retroconference.org/2010/Abstracts/39837.htm.
3. Barouch D.H. Challenges in the development of an HIV-1 vaccine. Nature 2008, 455:613-619.
4. Dolin R. HIV vaccine trial results-an opening for further research. N Engl J Med 2009, 361(23):2279-2280.
5. Newman P.A., Daley A., Halpenny R., Loutfy M. Community heroes or 'high-risk' pariahs? Reasons for declining to enroll in an HIV vaccine trial. Vaccine 2008, 26(8):1091-1097.
6. Newman P.A. Social and behavioral challenges of HIV vaccines: implications for social work and social science. Journal of HIV/AIDS & Social Services 2009, 8:313-330.
7. Buchbinder S.P., Mehrotra D.V., Duerr A., Fitzgerald D.W., Mogg R., Li D., et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008, 372(9653):1881-1893.
8. Vaccination and enrollment are discontinued in Phase II trials of Merck's investigational HIV vaccine candidate. News release. Sept 21, 2007. Available at: http://www.hvtn.org/pdf/FINAL_HIV_Vaccine_Press_Release.pdf.
9. STEP Study volunteers to be informed whether they received vaccine or placebo. News release Nov 13, 2007. Available at: http://www.hvtn.org/media/pr/step111307.html.
10. Corey L., McElrath M.J., Kublin J.G. Post-step modification for research on HIV vaccines. AIDS 2009, 23(1):3-8.
11. Newman P.A., Duan N., Roberts K.J., Seiden D., Rudy E.T., Swendeman D., et al. HIV vaccine trial participation among ethnic minority communities. J Acquir Immune Defic Syndr 2006, 41(2):210-217.
12. Allen M., Lau C.Y. Social impact of preventive vaccine clinical trial participation: a model of prevention, assessment and intervention. Soc Sci Med 2008, 66(4):945-951.
13. Koblin B.A., Holte S., Lenderking B., Heagerty P. Readiness for HIV vaccine trials: Changes in willingness and knowledge among high-risk populations in the HIV network for prevention trials. The HIVNET Vaccine Preparedness Study Protocol Team. J Acquir Immune Defic Syndr 2000, 24(5):451-457.
14. Mills E., Cooper C., Guyatt G., Gilchrist A., Rachlis B., Sulway C., et al. Barriers to participating in an HIV vaccine trial: a systematic review. AIDS 2004, 18:2235-2242.
15. Turner B.J., Cunningham W.E., Duan N., Andersen R.M., Shapiro M.F., Bozzette S.A., et al. Delayed medical care after diagnosis in a US national probability sample of persons infected with human immunodeficiency virus. Arch Intern Med 2000, 160(17):2614-2622.
16. Corbie-Smith G., Thomas S.B., St.George D.M. Distrust, race and research. Arch Intern Med 2002, 162:2458-2463.
17. Kegeles S.M., Johnson M.O., Strauss R.P., Ralston B., Hays R.B., Metzger D.S., et al. How should HIV vaccine efficacy trials be conducted? Diverse U.S. communities speak out. AIDS Educ Prev 2006, 18(6):560-572.
18. Lincoln Y.S., Guba E.G. Naturalistic inquiry 1985, Sage Publications, Newbury Park (CA).
19. Mays N., Pope C. Qualitative research in health care: assessing quality in qualitative research. BMJ 2000, 320(7226):50-52.
20. Charmaz K.C. Constructing grounded theory. A practical guide through qualitative analysis. 2006, Sage Publications, Thousand Oaks.
21. Glaser B.G. Theoretical sensitivity: advances in the methodology of grounded theory 1978, The Sociology Press, Mill Valley (CA).
22. HVTN 504 - Observational follow-up of adult participants enrolled in the Step Study (Merck V520 Protocol 023/HVTN 502). Available at http://www.hivinfrosource.org/hivis/clinicaltrials/prevention/hvtn504.html.
23. HIV Vaccine Trials Network. Press release: Step Study follow-up complete-First analyses presented at AIDS Vaccine 2010. Available at http://www.hvtn.org/media/pr/stepfollowup.html.
24. Featherstone K., Donovan J.L. Random allocation or allocation at random? Patients' perspectives of participation in a randomised controlled trial. BMJ 1998, 317:1177-1180.
25. Nilsen E.S., Myrhaug H.T., Johansen M., Oliver S., Oxman A.D. Methods of consumer involvement in developing healthcare policy and research, clinical practice guidelines and patient information material (review). Cochrane Database Syst Rev 2006, 3.
26. Lindegger G., Milford C., Slack C., Quayle M., Xaba X., Vardas E. Beyond the checklist: assessing understanding for HIV vaccine trial participation in South Africa. J Acquir Immune Defic Syndr 2006, 43:560-566.
27. Newman P.A. Towards a science of community engagement. Lancet 2006, 367(9507):302.
28. Campbell M.K., Snowdon C., Francis C., Elbourne D., McDonald A.M., Knight R., et al. Recruitment to randomised trials: strategies for trial enrolment and participation study. The STEPS study. Health Technol Assess 2007, 11(48).
29. Frew P.M., Mulligan M.J., Hou S.-I., Chan K., del Rio C. Time will tell: community acceptability of HIV vaccine research before and after the " Step Study" vaccine discontinuation. Open Access J Clin Trials 2010, 2:149-156.
30. Newman P.A., Duan N., Lee S.J., Rudy E.T., Seiden D., Kakinami L., Cunningham W.E. Willingness to participate in HIV vaccine trials among communities at risk: the impact of trial attributes. Prev Med 2007, 44:554-557.
31. Buchbinder S.P., Metch B., Holte S., Scheer S., Coletti A., Vittinghoff E. Determinants of enrollment in a preventive HIV vaccine trial: hypothetical versus actual willingness and barriers to participation. J Acquir Immune Defic Syndr 2004, 36:604-612.
32. Fernandez-Maldonado M.D., Segura P., Lama J.R., Sanchez J. Social factors affecting retention rates in Step study participants in Lima-Peru. Retrovirology 2009, 6(Suppl. 3):P217.
33. King M., Nazareth I., Lampe F., Bower P., Chandler M., Morou M., et al. Conceptual framework and systematic review of the effects of participants' and professionals' preferences in randomised controlled trials. Health Technol Assess 2005, 9(35).
34. Newman P.A., Seiden D., Roberts K., Duan N. A small dose of HIV? HIV vaccine mental models and risk communication. Health Educ Behav 2009, 36:321-333.
35. Newman P.A., Duan N., Kakinami L., Roberts K. What can HIV vaccine trials teach us about dissemination?. Vaccine 2008, 26(20):2528-2536.